Related Experiment Video
Updated: Mar 17, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
15.2K
Development of Antisense Drugs for Dyslipidemia
Tsuyoshi Yamamoto1, Fumito Wada, Mariko Harada-Shiba
1Graduate School of Pharmaceutical Sciences, Osaka University.
Journal of Atherosclerosis and Thrombosis
|July 29, 2016
Summary
Antisense oligonucleotides show promise for treating dyslipidemia by targeting specific genetic transcripts. This review explores advancements in antisense technology for improved drug potency and discusses their clinical potential for atherosclerosis.
Area of Science:
- Biochemistry
- Pharmacology
- Genetics
Background:
- Dyslipidemia, characterized by abnormal lipid levels (LDL, HDL, triglycerides), is a key factor in atherosclerosis development.
- Antisense oligonucleotides (ASOs) represent a therapeutic strategy targeting gene expression to manage dyslipidemia.
Purpose of the Study:
- To review the development and advancements of antisense oligonucleotides for dyslipidemia treatment.
- To highlight cutting-edge technologies enhancing ASO potency and delivery.
- To discuss the clinical perspectives and safety of ASOs for dyslipidemia.
Main Methods:
- Review of scientific literature on antisense oligonucleotide development for dyslipidemia.
- Analysis of recent technological innovations in ASO design and mechanisms.
- Evaluation of clinical trial outcomes and preclinical safety data.
Main Results:
- ASOs can effectively modulate various transcripts (mRNA, miRNA) to produce systemic anti-dyslipidemic effects.
- Recent technological advancements have significantly improved ASO pharmacokinetics and pharmacodynamics.
- Armed ASOs demonstrate potent therapeutic effects in preclinical and early clinical studies.
Conclusions:
- Antisense oligonucleotides offer a promising therapeutic avenue for dyslipidemia management.
- Continued research and clinical trials are essential to establish ASOs as a viable treatment option.
- Careful consideration of safety profiles is crucial for the clinical translation of ASO therapies.
More Related Videos
09:04Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
Published on: September 21, 2017
10.0K
08:18Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
Published on: July 27, 2022
1.7K
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
01:29Pharmacogenomics: Identification of New Drug Targets
73
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73
02:30siRNA - Small Interfering RNAs
18.9K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.9K
01:26Atherosclerosis III: Management
564
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
564
02:15Experimental RNAi
8.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.2K
01:27Bioavailability Enhancement: Drug Permeability Enhancement
292
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
292